PL3844147T3 - Związki chemiczne - Google Patents
Związki chemiczneInfo
- Publication number
- PL3844147T3 PL3844147T3 PL20816376.6T PL20816376T PL3844147T3 PL 3844147 T3 PL3844147 T3 PL 3844147T3 PL 20816376 T PL20816376 T PL 20816376T PL 3844147 T3 PL3844147 T3 PL 3844147T3
- Authority
- PL
- Poland
- Prior art keywords
- chemical compounds
- compounds
- chemical
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
- C07D209/16—Tryptamines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D209/20—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals substituted additionally by nitrogen atoms, e.g. tryptophane
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Addiction (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1916210.6A GB201916210D0 (en) | 2019-11-07 | 2019-11-07 | High purity tryptamines and methods of synthesis thereof |
| GBGB1917320.2A GB201917320D0 (en) | 2019-11-28 | 2019-11-28 | Novel compounds |
| GB2008303.6A GB2585978B (en) | 2019-06-03 | 2020-06-02 | Therapeutic compositions |
| PCT/EP2020/081502 WO2021089872A1 (en) | 2019-11-07 | 2020-11-09 | Compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3844147T3 true PL3844147T3 (pl) | 2022-07-18 |
Family
ID=75849570
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL20816375.8T PL3873883T3 (pl) | 2019-11-07 | 2020-11-09 | Sposób syntezy |
| PL20816376.6T PL3844147T3 (pl) | 2019-11-07 | 2020-11-09 | Związki chemiczne |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL20816375.8T PL3873883T3 (pl) | 2019-11-07 | 2020-11-09 | Sposób syntezy |
Country Status (18)
| Country | Link |
|---|---|
| US (6) | US11643390B2 (pl) |
| EP (3) | EP4180037A1 (pl) |
| JP (3) | JP7422473B2 (pl) |
| KR (2) | KR20230142817A (pl) |
| CN (2) | CN114829341B (pl) |
| AU (2) | AU2020381103B2 (pl) |
| BR (1) | BR112022008919A2 (pl) |
| CA (2) | CA3160334C (pl) |
| DK (1) | DK3844147T3 (pl) |
| ES (2) | ES2920681T3 (pl) |
| HR (2) | HRP20220797T1 (pl) |
| HU (2) | HUE061482T2 (pl) |
| IL (2) | IL292754B2 (pl) |
| MX (1) | MX2022005399A (pl) |
| NZ (1) | NZ788543A (pl) |
| PL (2) | PL3873883T3 (pl) |
| PT (2) | PT3873883T (pl) |
| WO (2) | WO2021089873A1 (pl) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201907871D0 (en) | 2019-06-03 | 2019-07-17 | Small Pharma Ltd | Therapeutic compositions |
| EP3753923A1 (en) | 2019-06-19 | 2020-12-23 | GH Research Limited | Recrystallisation of 5-methoxy-n,n-dimethyltryptamine (5-meo-dmt) in methyl tert.-butyl ether (mtbe) without adding an anti-solvent |
| EP4180037A1 (en) | 2019-11-07 | 2023-05-17 | Small Pharma Ltd | Method of synthesis |
| IL327334A (en) | 2020-02-04 | 2026-05-01 | Mindset Pharma Inc | Psilocin derivatives as serotonergic psychedelics for the treatment of central nervous system disorders |
| US11332441B2 (en) * | 2020-03-23 | 2022-05-17 | Caamtech, Inc. | Crystalline N-methyl tryptamine derivatives |
| EP4146198A4 (en) | 2020-05-08 | 2024-05-15 | Psilera Inc. | Novel compositions of matter and pharmaceutical compositions |
| US12240813B2 (en) | 2020-05-19 | 2025-03-04 | Cybin Irl Limited | Deuterated tryptamine derivatives and methods of use |
| US11773062B2 (en) | 2021-03-22 | 2023-10-03 | Small Pharma Ltd | Deuterated compounds |
| CN116056763B (zh) * | 2020-06-02 | 2024-03-05 | 赛本英国有限公司 | 包含氘代或部分氘代的n,n-二甲基色胺化合物的治疗组合物 |
| US12042564B2 (en) | 2020-06-02 | 2024-07-23 | Cybin Uk Ltd | Therapeutic solid dosage forms |
| EP3902541B1 (en) * | 2020-06-02 | 2022-09-14 | Small Pharma Ltd | Therapeutic compositions comprising deuterated or partially deuterated n,n-dimethyltryptamine compounds |
| KR20230024378A (ko) | 2020-06-12 | 2023-02-20 | 벡클리 싸이테크 리미티드 | 5-메톡시-n, n-디메틸트립타민의 벤조에이트 염을 포함하는 조성물 |
| US11406619B2 (en) | 2020-08-28 | 2022-08-09 | Small Pharma Ltd | Injectable formulations |
| US12521370B2 (en) | 2020-12-01 | 2026-01-13 | Cybin Uk Ltd | Inhalable formulations |
| US11660289B2 (en) | 2020-12-01 | 2023-05-30 | Small Pharma Ltd. | Deuterated or partially deuterated N,N-dimethyltryptamine compounds |
| WO2022153266A1 (en) | 2021-01-15 | 2022-07-21 | Beckley Psytech Limited | Ergoline analogues |
| US12534441B2 (en) | 2021-01-15 | 2026-01-27 | Beckley Psytech Limited | Tryptamine analogues |
| US11312684B1 (en) | 2021-02-10 | 2022-04-26 | Eleusis Therapeutics Us, Inc. | Pharmaceutically acceptable salts of psilocin and uses thereof |
| CA3218110A1 (en) | 2021-05-25 | 2022-12-01 | Majed Fawaz | New n,n-dimethyltryptamine salts and crystalline salt forms |
| US20230041584A1 (en) | 2021-06-09 | 2023-02-09 | ATAI Life Sciences AG | Novel prodrugs and conjugates of dimethyltryptamine |
| EP4122916A1 (en) * | 2021-07-22 | 2023-01-25 | GH Research Ireland Limited | Method for preparing an organic compound |
| IL310296A (en) * | 2021-07-22 | 2024-03-01 | Gh Res Ireland Limited | A method for the preparation of a tryptamine derivative |
| US11697638B2 (en) * | 2021-09-08 | 2023-07-11 | Small Pharma Ltd | 5-methoxy-N,N-dimethyltryptamine crystalline forms |
| EP4159192A1 (en) | 2021-09-30 | 2023-04-05 | Biomind Labs Inc | Dimethyltriptamine-based nasal spray for the personalised treatment of neurological and psychiatric disorders |
| IL312859A (en) | 2021-11-18 | 2024-07-01 | Cybin Uk Ltd | Injectable and inhalable formulations |
| US12318477B2 (en) | 2021-11-18 | 2025-06-03 | Cybin Uk Ltd | Injectable and inhalable formulations |
| WO2023108174A1 (en) * | 2021-12-10 | 2023-06-15 | Terran Biosciences, Inc. | Analogs of 6-methoxy- n, n-dimethyltryptamine |
| EP4457214A4 (en) | 2021-12-30 | 2025-12-03 | Atai Therapeutics Inc | DIMETHYLTRYPTAMINE ANALOGUES USED AS NITRIC OXIDE ADMINISTRATION MEDICINES |
| WO2023147423A1 (en) * | 2022-01-28 | 2023-08-03 | Miralogx Llc | Anxiolytic compounds, pharmaceutical compositions, and methods of treating anxiety and other disorders |
| EP4486448A1 (en) | 2022-03-04 | 2025-01-08 | Reset Pharmaceuticals, Inc. | Co-crystals or salts comprising psilocin |
| US20230346718A1 (en) * | 2022-04-27 | 2023-11-02 | Yale University | Method of treating, ameliorating and/or preventing depression |
| US12264131B2 (en) | 2022-08-19 | 2025-04-01 | Beckley Psytech Limited | Pharmaceutically acceptable salts and compositions thereof |
| GB202212116D0 (en) | 2022-08-19 | 2022-10-05 | Beckley Psytech Ltd | Pharmaceutically acceptable salts and Compositions thereof |
| EP4601639A1 (en) | 2022-10-13 | 2025-08-20 | Cybin UK Ltd | Method of administration of a parenteral formulation comprising a psychedelic agent |
| AU2023383549A1 (en) | 2022-11-17 | 2025-06-05 | Remedi, Inc. | Combinations of monoamine oxidase inhibitors and serotonin receptor agonists and their therapeutic use |
| TW202430149A (zh) * | 2022-12-01 | 2024-08-01 | 美商雅特益醫療公司 | Ｎ，ｎ－二甲基色胺之結晶形式及其使用方法 |
| IL322260A (en) | 2023-01-23 | 2025-09-01 | Cybin Uk Ltd | Treatment of psychiatric or neurological diseases by parenteral administration of a single, effective parenteral dose of a short-acting psychedelic substance |
| EP4687862A1 (en) | 2023-03-31 | 2026-02-11 | Cybin UK Ltd | Combination comprising a monoamine antidepressant agent and a short-duration psychedelic agent |
| US12246005B2 (en) | 2023-06-13 | 2025-03-11 | Beckley Psytech Limited | 5-methoxy-n,n-dimethyltryptamine (5-MeO-DMT) formulations |
| US12180158B1 (en) * | 2023-08-03 | 2024-12-31 | Gilgamesh Pharmaceuticals, Inc. | Crystalline fumarate salts of n-ethyl-2-(5-fluoro-1H-indol-3-yl)-n-methylethan-1-amine |
| US12129234B1 (en) * | 2023-08-03 | 2024-10-29 | Gilgamesh Pharmaceuticals, Inc. | Crystalline salts of N-ethyl-(5-fluoro-1H-indol-3-yl)-N-methylethan-1-amine |
| WO2026013174A1 (en) | 2024-07-10 | 2026-01-15 | Cybin Uk Ltd | Pharmaceutical compositions comprising deuterated n,n-dimethyltryptamine |
Family Cites Families (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4336378A (en) | 1980-04-10 | 1982-06-22 | Sandoz, Inc. | Isoxazolyl indolamines |
| CA2110574A1 (en) * | 1991-06-21 | 1993-01-07 | Lawrence I. Kruse | Tryptamine analogues, their synthesis and their use as 5-ht1-like or 5-ht2 receptor agonists |
| US6376531B1 (en) | 1998-11-13 | 2002-04-23 | Rupert Charles Bell | Method of treatment using deuterium compounds |
| AU6689601A (en) | 2000-06-16 | 2002-01-02 | Rtp Pharma Inc | Improved injectable dispersions of propofol |
| WO2004085392A1 (en) | 2003-03-25 | 2004-10-07 | Faust Pharmaceuticals | Melatonin derivatives and their use for treating neurological dysfunctions |
| BRPI0715579A2 (pt) | 2006-10-19 | 2015-05-26 | Auspex Pharmaceuticals Inc | "composto, composição farmacêutica e uso de um composto" |
| WO2008071455A1 (en) | 2006-12-15 | 2008-06-19 | Bayer Schering Pharma Aktiengesellschaft | Bicyclic acyltryptophanols |
| CZ302424B6 (cs) * | 2007-06-13 | 2011-05-11 | Zentiva, A. S. | Zpusob prípravy almotriptanu o vysoké cistote |
| SG10201705968RA (en) * | 2007-08-06 | 2017-08-30 | Biotie Therapies Inc | Methods for treating dependence |
| US20090076121A1 (en) | 2007-09-14 | 2009-03-19 | Protia, Llc | Deuterium-enriched sumatriptan |
| WO2009049030A1 (en) | 2007-10-09 | 2009-04-16 | Triton Biopharma, Llc | Method to use compositions having antidepressant anxiolytic and other neurological activity and compositions of matter |
| US20100113496A1 (en) * | 2008-09-25 | 2010-05-06 | Auspex Pharmaceuticals, Inc. | Piperidine modulators of vmat2 |
| WO2013063492A1 (en) | 2011-10-28 | 2013-05-02 | Board Of Regents, The University Of Texas System | Novel compositions and methods for treating cancer |
| CA2883641C (en) * | 2012-09-18 | 2021-09-14 | Auspex Pharmaceuticals, Inc. | Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2 |
| CN108299400B (zh) * | 2013-03-14 | 2021-02-19 | 达特神经科学(开曼)有限公司 | 作为pde4抑制剂的取代的吡啶和取代的吡嗪化合物 |
| IL285760B2 (en) * | 2014-09-02 | 2025-03-01 | Bhupinder Singh | Deuterated or a non-deuterated molecule and pharmaceutical formulations |
| WO2016181414A1 (en) * | 2015-05-12 | 2016-11-17 | Council Of Scientific & Industrial Research | Process for the synthesis of ivacaftor and related compounds |
| WO2018064465A1 (en) * | 2016-09-29 | 2018-04-05 | The Regents Of The University Of California | Compounds for increasing neural plasticity |
| CA3052974A1 (en) | 2017-02-09 | 2018-08-16 | CaaMTech, LLC | Compositions and methods comprising a psilocybin derivative |
| WO2018195455A1 (en) | 2017-04-20 | 2018-10-25 | Eleusis Benefit Corporation, Pbc | Assessing and treating psychedelic-responsive subjects |
| GB2571696B (en) | 2017-10-09 | 2020-05-27 | Compass Pathways Ltd | Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced |
| EP3713568A1 (en) * | 2017-10-26 | 2020-09-30 | Consejo Superior de Investigaciones Cientificas (CSIC) | Combination product for the treatment of neurological and/or psychiatric disorders |
| WO2019089902A1 (en) | 2017-11-01 | 2019-05-09 | Drexel University | Compounds, compositions, and methods for treating diseases |
| AU2020225766B2 (en) | 2019-02-22 | 2025-10-30 | GH Research Ireland Limited | Compositions comprising 5-Methoxy-N,N-dimethyltryptamine (5-MeO-DMT) for use in treating mental disorders |
| EA202192318A1 (ru) | 2019-02-22 | 2021-12-21 | Гх Рисерч Айрленд Лимитед | 5-метокси-n,n-диметилтриптамин (5-meo-dmt) для лечения депрессии |
| JP7770673B2 (ja) | 2019-02-27 | 2025-11-17 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 脳障害を治療するためのアゼピノ－インドール及び他の複素環化合物 |
| WO2020176597A1 (en) * | 2019-02-27 | 2020-09-03 | The Regents Of The University Of California | N-substituted indoles and other heterocycles for treating brain disorders |
| GB201907871D0 (en) | 2019-06-03 | 2019-07-17 | Small Pharma Ltd | Therapeutic compositions |
| EP4180037A1 (en) | 2019-11-07 | 2023-05-17 | Small Pharma Ltd | Method of synthesis |
| CN111072492A (zh) * | 2019-11-29 | 2020-04-28 | 浙江工业大学 | 一种合成3,4-二氯-2-氨基-5-氟联苯的方法 |
| IL327334A (en) | 2020-02-04 | 2026-05-01 | Mindset Pharma Inc | Psilocin derivatives as serotonergic psychedelics for the treatment of central nervous system disorders |
| WO2021234608A1 (en) | 2020-05-19 | 2021-11-25 | Cybin Irl Limited | Deuterated tryptamine derivatives and methods of use |
| US12240813B2 (en) | 2020-05-19 | 2025-03-04 | Cybin Irl Limited | Deuterated tryptamine derivatives and methods of use |
| US11773062B2 (en) | 2021-03-22 | 2023-10-03 | Small Pharma Ltd | Deuterated compounds |
| US12042564B2 (en) | 2020-06-02 | 2024-07-23 | Cybin Uk Ltd | Therapeutic solid dosage forms |
| EP3902541B1 (en) | 2020-06-02 | 2022-09-14 | Small Pharma Ltd | Therapeutic compositions comprising deuterated or partially deuterated n,n-dimethyltryptamine compounds |
| GB202008961D0 (en) | 2020-06-12 | 2020-07-29 | Beckley Psytech Ltd | Pharmaceutical composition |
| US20220040150A1 (en) | 2020-08-05 | 2022-02-10 | Universitatsspital Basel | Intravenous dmt administration method for dmt-assisted psychotherapy |
| IL298129B2 (en) | 2020-08-28 | 2024-11-01 | Cybin Uk Ltd | An injectable formulation containing the fumarate salt of dimethyltryptamine or deuterium-containing dimethyltryptamine |
| US20220062237A1 (en) | 2020-08-28 | 2022-03-03 | Small Pharma Ltd | Injectable formulation |
| US11406619B2 (en) | 2020-08-28 | 2022-08-09 | Small Pharma Ltd | Injectable formulations |
| US20230355583A1 (en) | 2020-10-02 | 2023-11-09 | Cybin Irl Limited | Methods for delivery of psychedelic medications by inhalation and systems for performing the methods |
| US11000534B1 (en) | 2020-10-08 | 2021-05-11 | Lennham Pharmaceuticals, Inc. | Deuterated derivatives of psilocybin and uses thereof |
| EP4255421A1 (en) | 2020-12-01 | 2023-10-11 | Small Pharma Ltd | Inhalable formulations |
| US12521370B2 (en) | 2020-12-01 | 2026-01-13 | Cybin Uk Ltd | Inhalable formulations |
| US11660289B2 (en) | 2020-12-01 | 2023-05-30 | Small Pharma Ltd. | Deuterated or partially deuterated N,N-dimethyltryptamine compounds |
| EP4031529B1 (en) | 2020-12-01 | 2023-09-27 | Small Pharma Ltd | Deuterated or partially deuterated n,n-dimethyltryptamine compounds |
| US11697638B2 (en) | 2021-09-08 | 2023-07-11 | Small Pharma Ltd | 5-methoxy-N,N-dimethyltryptamine crystalline forms |
| US12318477B2 (en) | 2021-11-18 | 2025-06-03 | Cybin Uk Ltd | Injectable and inhalable formulations |
-
2020
- 2020-11-09 EP EP22214748.0A patent/EP4180037A1/en active Pending
- 2020-11-09 IL IL292754A patent/IL292754B2/en unknown
- 2020-11-09 CN CN202080087092.5A patent/CN114829341B/zh active Active
- 2020-11-09 WO PCT/EP2020/081503 patent/WO2021089873A1/en not_active Ceased
- 2020-11-09 HU HUE20816375A patent/HUE061482T2/hu unknown
- 2020-11-09 JP JP2022526073A patent/JP7422473B2/ja active Active
- 2020-11-09 CA CA3160334A patent/CA3160334C/en active Active
- 2020-11-09 KR KR1020237033500A patent/KR20230142817A/ko not_active Ceased
- 2020-11-09 WO PCT/EP2020/081502 patent/WO2021089872A1/en not_active Ceased
- 2020-11-09 CA CA3160337A patent/CA3160337C/en active Active
- 2020-11-09 EP EP20816375.8A patent/EP3873883B1/en active Active
- 2020-11-09 AU AU2020381103A patent/AU2020381103B2/en active Active
- 2020-11-09 EP EP20816376.6A patent/EP3844147B1/en active Active
- 2020-11-09 PT PT208163758T patent/PT3873883T/pt unknown
- 2020-11-09 BR BR112022008919A patent/BR112022008919A2/pt not_active Application Discontinuation
- 2020-11-09 HU HUE20816376A patent/HUE059403T2/hu unknown
- 2020-11-09 PL PL20816375.8T patent/PL3873883T3/pl unknown
- 2020-11-09 CN CN202080087091.0A patent/CN114829340B/zh active Active
- 2020-11-09 HR HRP20220797TT patent/HRP20220797T1/hr unknown
- 2020-11-09 HR HRP20230281TT patent/HRP20230281T1/hr unknown
- 2020-11-09 PL PL20816376.6T patent/PL3844147T3/pl unknown
- 2020-11-09 PT PT208163766T patent/PT3844147T/pt unknown
- 2020-11-09 NZ NZ788543A patent/NZ788543A/en unknown
- 2020-11-09 ES ES20816376T patent/ES2920681T3/es active Active
- 2020-11-09 JP JP2022526074A patent/JP7423131B2/ja active Active
- 2020-11-09 AU AU2020378647A patent/AU2020378647B2/en active Active
- 2020-11-09 IL IL292753A patent/IL292753B2/en unknown
- 2020-11-09 DK DK20816376.6T patent/DK3844147T3/da active
- 2020-11-09 ES ES20816375T patent/ES2940811T3/es active Active
- 2020-11-09 KR KR1020227018623A patent/KR20220082092A/ko not_active Ceased
- 2020-11-09 MX MX2022005399A patent/MX2022005399A/es unknown
-
2021
- 2021-08-26 US US17/412,828 patent/US11643390B2/en active Active
-
2022
- 2022-05-06 US US17/662,261 patent/US11578039B2/en active Active
-
2023
- 2023-01-10 US US18/152,465 patent/US12157723B2/en active Active
- 2023-03-31 US US18/193,866 patent/US12084417B2/en active Active
- 2023-11-30 JP JP2023202672A patent/JP7748437B2/ja active Active
-
2024
- 2024-03-12 US US18/602,171 patent/US20240217929A1/en active Pending
- 2024-10-21 US US18/921,515 patent/US20250042852A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL292753A (en) | Compounds | |
| IL286833A (en) | Compositions containing brazzein | |
| IL283692A (en) | Novel composition | |
| DK3956033T3 (da) | Bicykliske forbindelser | |
| DK4165024T3 (da) | Cyclobutyldihydroquinolinsulfonamid-forbindelser | |
| DK3692040T3 (da) | Kemiske forbindelser | |
| LT3810602T (lt) | Junginiai | |
| EP4129997A4 (en) | Octahydropyrazinodiazanaphthyridine dione compounds | |
| DK4083038T3 (da) | Pyridazinylthiazolcarboxamidforbindelse | |
| DK3768271T3 (da) | Organiske forbindelser | |
| IL310528A (en) | Pyrazolopyridinone compounds | |
| EP4149556C0 (en) | PEG LIPIDOIDS COMPOUNDS | |
| PL4039675T3 (pl) | Związki fenylo-2-hydroksyacetyloamino-2-metylo-fenylowe | |
| DK4320112T3 (da) | Pyridinylsubstituerede oxoisoindolinforbindelser | |
| DK3762378T3 (da) | Herbicide forbindelser | |
| IL288608A (en) | Etching compositions | |
| EP3790385A4 (en) | STABILIZED CHEMICAL COMPOSITION | |
| HUE065134T2 (hu) | Vegyületek | |
| IL291119A (en) | Etching composition | |
| LT3867247T (lt) | Naujieji junginiai | |
| DK3808747T3 (da) | Imidazopyridinon-forbindelse | |
| EP4143199C0 (en) | NUCLEOTIDE PROMEDICINAL COMPOUNDS | |
| IL287919A (en) | Chemical process | |
| IL287656A (en) | Etching compositions | |
| IL288684A (en) | Etching compositions |